Market Updates, Products & Ingredients

Protein Brand David Closes $75 Million Series A Funding Round

Company acquires food tech firm Epogee, which produces a plant-based fat alternative.

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Photo courtesy of David

David, whose flagship protein bar features 28 grams of protein, zero sugar, and 150 calories, has closed a $75 million Series A funding round, led by Greenoaks with the participation of Valor Equity Partners.

Focused on increasing muscle and decreasing fat, David debuted its signature protein bar in September 2024. Since then, the brand has expanded into over 3,000 retail locations across the U.S., most recently entering Wegmans. The brand is on pace to surpass $100 million in revenue in its first year of operation, the company said.

“Our mission is simple: to remove unnecessary calories and sugar from the American diet and replace them with what the body actually needs, which is high-quality protein,” said Peter Rahal, co-founder and CEO. “We’re building tools that make it easier to eat well without compromise. The response to David has been overwhelming, and this funding allows us to scale faster and stay focused on our mission of providing solutions to support and improve people’s health and well-being.”

David will use the investment to scale manufacturing, accelerate product development, and expand inventory to meet surging demand across retail and e-commerce. As part of this growth strategy, the company has acquired Epogee, the food technology firm behind EPG, a plant-based fat alternative that significantly reduces calories and fat without compromising taste or texture.

“We are not here to make another snack. We are here to advance nutrition,” added Rahal. “Acquiring Epogee strengthens our ability to scale by securing a key ingredient that helps us reduce calories and fat without compromising taste. This is about gaining control over our supply chain to move faster, stay true to our mission, and deliver food that improves health.”

In August 2024, David closed a $10 million seed funding round. Notable investors include Layne Norton, PhD, Andrew Huberman, PhD, and Dr. Peter Attia, MD, who serves as the brand’s chief science officer.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters